Development and Optimization of a Potency Assay for a 7 Component Peptide Drug
Optimization of Ligand Binding Assay by Design of Experiment
A Regulatory Perspective on Bioassays for Evaluation of the Quality of Protein Drug Products
Reference Standards for Potency Assays – Future Directions
A Statistical Approach to Bioassay Bridging and Transfer
Compendial Potency Assays and Associated Biological Reference Materials – Challenges in Assay Transition and Unit Maintenance
Evaluation of Processes for Reducing and Monitoring Assay Variability for Bioassays
Regulatory-Compliant Validation of a Standardized ADCC Potency Assay
Assay Development, Automation and De-Convolution of Multiplexed High Throughput Live-Cell Screens
Bioluminescent NFAT-RE-luciferase Reporter Bioassay: A Novel Technology to Reduce Assay Variability in ADCC
Functional Assays for Biosimilars: An Industry Perspective
Special Considerations for Developing Cell-Based Immunogenicity Neutralizing Anti-Drug Antibody (NAb) Assays to Support Clinical Comparability Studies for Biosimilars
Characterization Using a Surrogate Non Cell-Based Ligand Binding Assay
Comparison of Cell-Based and Non Cell-Based Assay Platforms for the Detection of Anti-Drug Neutralizing Antibodies
Who should Attend
Attendess involved in
Cell and antibody engineering
Bioanalytical R&D
Pharmacology
Immunology
Preclinical and clinical development
Past Events
CHI`s Optimizing Bioassays for Biologics 2013 - 12-13 Nov 2013, Hyatt Regency Washington on Capitol Hill, District of Columbia, United States (40357)
Important
Please, check "CHI`s Optimizing Bioassays for Biologics" official website for possible changes, before making any traveling arrangements
